/PRNewswire/ Data Bridge Market research has recently released expansive research titled "Global Human Microbiome Market" guarantees you will remain better.
/PRNewswire/ The "Microbiome Global Market Report 2022: By Type, By Application, By Technology" report has been added to ResearchAndMarkets.com s offering..
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.
The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth.
However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market s growth.
Global Human Microbiome Markets, 2021-2028 - Opportunities in Increasing Collaborations Between Public-Private Organizations prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(CSE: FOG.X) (OTCB: FOGCF) (FRA: MUU3) (the
Company or
FogChain ) is pleased to announce, further to its news release dated January 13, 2021, the Company has entered into a merger agreement and plan of reorganization (the
Definitive Agreement ) with Avisa Pharma Inc. (
Avisa ) and FogChain USA Inc., a wholly-owned subsidiary of FogChain, dated February 1, 2021, in respect of a statutory merger under the Delaware General Corporation Law pursuant to which the Company has agreed to acquire all of the issued and outstanding shares in the capital of Avisa (the
Avisa Shares ), a privately held Delaware company, in exchange for the issuance of approximately 33,263,123 common shares and 14,825,786 restricted voting shares in the capital of the Company (the